Frequent cystoscopy for monitoring nonmuscle-invasive bladder cancer (NMIBC) is burdensome and costly, prompting a search for alternatives.

Nine years after my bladder cancer diagnosis, I reflect on its recurrence, caregiving, grief, and my new life with leukemia and renewed gratitude.

The FDA designates the TOBY Test as a breakthrough device, revolutionizing bladder cancer detection with a non-invasive, AI-driven urine test.

Discover a study exploring novel drug combinations and genetic insights transforming advanced bladder cancer treatment.

Every bladder cancer journey is different, and no single treatment or diagnostic path fits everyone. According to patients who have experienced bladder cancer, the best care for you will depend on ...

The Food and Drug Administration (FDA) has granted Priority Review to TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle invasive bladder ...

An expert discusses how recent updates to AUA, EAU and NCCN guidelines have cautiously shifted toward more bladder-sparing approaches for BCG-unresponsive patients, incorporating new FDA-approved ...

The FDA has granted RMAT designation to detalimogene voraplasmid for the treatment of high-risk, BCG-unresponsive, NMIBC with CIS.

Normally, the sphincter remains closed as the bladder fills with urine. The weakened muscles and relaxed pelvic floor have ...

There is limited research on chronic pelvic pain in men, which delays treatment for male patients experiencing symptoms of ...

Blood in urine may signal serious issues—from infections to cancers. Experts stress early evaluation, especially in older adults, to ensure timely, potentially life-saving treatment.

This is kind of embarrassing, but, for a while, I’ve been leaking urine. Can something be done to fix this incontinence ...